ePrints

New developments in Sjogren's syndrome

Lookup NU author(s): Dr Nishanthi Thalayasingam, Professor Fai NgORCiD

Downloads

Full text for this publication is not currently held within this repository. Alternative links are provided below where available.

Abstract

© The Author(s) 2021. Published by Oxford University Press on behalf of the British Society for Rheumatology.SS is a chronic, autoimmune condition characterized by lymphocytic infiltration of the exocrine glands and B-cell dysfunction. Current treatment strategies are largely empirical and offer only symptomatic relief for patients. There are no proven treatments that alter disease progression or treat the systemic manifestations of disease. B-cell depletion is used in patients with systemic disease but its overall clinical efficacy has not been demonstrated in two large randomized controlled trials. Studies are now focussing on alternative strategies to target B-cells, including co-stimulation targets, with promising data. It is increasingly clear that clinical trials in SS will require patient stratification and relevant and sensitive outcome measures to identify successful treatment modalities.

Publication metadata

Author(s): Thalayasingam N, Baldwin K, Judd C, Ng W-F

Publication type: Article

Publication status: Published

Journal: Rheumatology

Year: 2021

Volume: 60

Issue: 6

Pages: vi53-vi61

Online publication date: 24/12/2021

Acceptance date: 17/05/2021

ISSN (print): 1462-0324

ISSN (electronic): 1462-0332

Publisher: Oxford University Press

URL: https://doi.org/10.1093/rheumatology/keab466

DOI: 10.1093/rheumatology/keab466

PubMed id: 34951923

Altmetrics

Share